Diverse proteins with accessible nucleophilic residues

Diverse proteins with accessible nucleophilic residues represent a broad and heterogeneous class of biological entities defined by their chemical reactivity rather than a shared evolutionary lineage or specific biological family. These proteins contain specific amino acids—most commonly cysteine, lysine, serine, or threonine—with side chains capable of donating electrons to form covalent bonds with electrophilic compounds (Singh et al., 2011, Nature Reviews Drug Discovery). In modern pharmacology, these residues are strategically targeted by covalent inhibitors to achieve high potency and a prolonged duration of action that is often independent of the drug's systemic half-life (Bauer, 2015, Royal Society of Chemistry). This target class spans various functional categories, including kinases like Bruton's tyrosine kinase (BTK) and the Epidermal Growth Factor Receptor (EGFR), as well as viral proteases and metabolic enzymes (Resnick et al., 2019, Cell Chemical Biology). While targeting these residues allows for the potent inhibition of proteins previously considered 'undruggable,' it also presents significant challenges regarding selectivity. The primary risk involves off-target reactivity and the potential for immunogenicity through the formation of protein-drug adducts, known as haptens, which can trigger adverse immune responses (Gehringer & Laufer, 2019, Journal of Medicinal Chemistry). Consequently, the development of therapeutics for this 'nucleophilic proteome' requires the precise calibration of electrophilic reactivity to ensure a balance between therapeutic efficacy and safety.

Other names

Nucleophilic proteomeCysteinomeLysinomeCovalent drug targetsReactive proteome

Covalent modification of nucleophilic amino acid residues (e.g., cysteine, lysine, serine, or threonine) via electrophilic functional groups (warheads) on a drug molecule, resulting in the formation of a stable chemical bond and subsequent inhibition or modulation of the protein's activity.